Evidence map›Paper›PMID 40256911›Full record

ArticleAnnals of clinical and translational neurology2025

A 14-Year Study of Serum Glial Fibrillary Acidic Protein and Total Tau in Premanifest Huntington's.

Natalia E Owen, Zanna J Voysey, Jonathan A Holbrook, Maura Malpetti, Clara Le Draoulec, Lennart R B Spindler, Anna O G Goodman, Alpar S Lazar, Roger A Barker

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of clinical and translational neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Stage-dependent tau-PET signatures in Huntington's disease revealed by [¹⁸F]PI-2620.European journal of nuclear medicine and molecular imaging · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Natalia E OwenDepartment of Clinical Neurosciences, John van Geest Centre for Brain Repair, University of Cambridge, Cambridge, UK.ORCID 0009-0008-0089-9120
Zanna J VoyseyDepartment of Clinical Neurosciences, John van Geest Centre for Brain Repair, University of Cambridge, Cambridge, UK.
Jonathan A HolbrookDepartment of Clinical Neurosciences, John van Geest Centre for Brain Repair, University of Cambridge, Cambridge, UK.
Maura MalpettiDepartment of Clinical Neurosciences, Cambridge Centre for Frontotemporal Dementia and Related Disorders, University of Cambridge, Cambridge, UK.ORCID 0000-0001-8923-9656
Clara Le DraoulecDepartment of Clinical Neurosciences, John van Geest Centre for Brain Repair, University of Cambridge, Cambridge, UK.
Lennart R B SpindlerDepartment of Clinical Neurosciences, John van Geest Centre for Brain Repair, University of Cambridge, Cambridge, UK.
Anna O G GoodmanDepartment of Clinical Neurosciences, John van Geest Centre for Brain Repair, University of Cambridge, Cambridge, UK.
Alpar S LazarFaculty of Medicine and Health Sciences, University of East Anglia, Norwich, UK.
Roger A BarkerDepartment of Clinical Neurosciences, John van Geest Centre for Brain Repair, University of Cambridge, Cambridge, UK.

Funding

Alzheimer's Research UK ARUK-RADF2021A-010Association of British Neurologists/Guarantors of Brain Clinical Research FellowshipCentre Parkinson Plus Grant and Cure Parkinson's TrustNIHR Cambridge Biomedical Research Centre BRC-1215-20014UK Medical Research CouncilUKRI Medical Research Council MC_PC_17230Wellcome TrustWellcome Trust 203151/A/16/ZWellcome Trust 203151/Z/16/Z
6 · The paper itself

Abstract

There is a pressing need for blood biomarkers that can identify Huntington's disease (HD) gene carriers' proximity to manifest disease. We previously examined serial serum neurofilament light (NfL) concentrations in 21 premanifest HD gene carriers and 14 controls over 14 years, finding that NfL demonstrates high prognostic value and distinct longitudinal dynamics in premanifest/transitional HD. Here, we report the corresponding results for serum glial fibrillary acidic protein and total tau, providing the first longitudinal and head-to-head study of these biomarkers in HD. Our findings do not support the utility of these analytes as prognostic biomarkers in premanifest and transitional HD.

Indexed as

Glial Fibrillary Acidic ProteinHuntington Diseasetau ProteinsAdultBiomarkersFemaleHumansLongitudinal StudiesMaleMiddle AgedNeurofilament ProteinsBiomarkersGFAP protein, humanGlial Fibrillary Acidic ProteinMAPT protein, humanneurofilament protein LNeurofilament Proteinstau Proteinsblood‐based biomarkersglial fibrillary acidic proteinHuntington's diseaseprognostic biomarkerstau

Identifiers

PMID40256911
PMCPMC12172102

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.